Peré Domingo - Infectious Diseases

Author Information

Pere Domingo is a distinguished researcher affiliated with the Infectious Diseases Unit at the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain. His work primarily focuses on infectious diseases, with a significant emphasis on HIV and COVID-19. Dr. Domingo's research is critical in advancing understanding and treatment options in these areas, contributing to significant improvements in patient care and therapeutic strategies.

Research Contributions

Pere Domingo has made substantial contributions to the field of infectious diseases, particularly in the context of HIV and COVID-19. In 2022 alone, he published several influential papers exploring various aspects of HIV treatment, such as antiretroviral therapies, metabolic disorders associated with HIV, and biomarkers of immune recovery. His research also extends to COVID-19, where he has investigated clinical management, potential biomarkers for pneumonia, and neuropsychological impacts post-infection. His work on the effects of valproic acid in COVID-19 patients and the atherogenicity of low-density lipoproteins in HIV patients illustrates his commitment to addressing complex challenges in infectious disease management.

Aliases

Pere Domingo is also known by several aliases in academic publications, including P Domingo and Peré Domingo. These variations are commonly encountered across different databases and journals, reflecting slight differences in the representation of his name.

Publication and Citation Metrics

Metric	Value
Total Citation Count	14,613
H-index	60
Total Paper Count	575

Publications:

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

DOI: 10.1093/ofid/ofab595

Year: 2022

Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

DOI: 10.1007/s40121-022-00630-y

Year: 2022

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

DOI: 10.3390/jcm11030549

Year: 2022

Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy

DOI: 10.1080/21623945.2022.2042962

Year: 2022

Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy

DOI: 10.3390/ijms23042202

Year: 2022

Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission

DOI: 10.1038/s41598-021-04683-w

Year: 2022

Determinants of Long-Term Survival in Late HIV Diagnosed Individuals: A Prospective Cohort Study

DOI: 10.2139/ssrn.4082916

Year: 2022

Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19

DOI: 10.1371/journal.pone.0262777

Year: 2022

Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.

DOI: 10.1093/jac/dkac117

Year: 2022

Neuropsychological deficits in patients with cognitive complaints after COVID‐19

DOI: 10.1002/brb3.2508

Year: 2022

What Are Antibiotics and How Do They Work?

Can Infectious Diseases Be Prevented?

How Can Avian Influenza be Prevented?

Where is Yellow Fever Found?

What Future Directions is the NIH Taking in Infectious Disease Research?

What Are the Potential Complications?

How is E. Coli Diagnosed?

How Are STIs Diagnosed?

What is Resource Allocation in Infectious Diseases?

Is Colonization Harmful?

Partnered Content Networks

Relevant Topics